

1 **Title:**

2 **COVID-19 and the long-term cardio-respiratory and metabolic health**
3 **complications**

4

5 Authors:

6 Ashton, R.E.,¹ Ansdell, P.,^{2?} Hume, E.,^{2?} Maden-Wilkinson, T.,^{3?} Ryan, D.,^{4?} Tuttiett,
7 E.R.,^{5?} & Faghy, M.A.¹

8

9 Affiliations:

- 10 1. Human Sciences Research Centre, University of Derby, England, DE22 1GB
- 11 2. Department of Sport, Exercise and Rehabilitation, Northumbria University,
12 England, NE1 8ST
- 13 3. Advanced Well-being Research Centre, Sheffield Hallam University, England,
14 S9 3TU
- 15 4. Centre for Physical Activity and Life Sciences, University of Northampton,
16 Northampton, England, NN1 5PH
- 17 5. Department of Oncology and Metabolism, The Medical School, University of
18 Sheffield, England, S19 2RX

19

20 Email addresses:

21 Ruth Ashton: r.ashton@derby.ac.uk
22 Paul Ansdell: p.ansdell@northumbria.ac.uk
23 Emily Hume: emily.c.hume@northumbria.ac.uk
24 Tom Maden-Wilkinson: t.maden-wilkinson@shu.ac.uk
25 Declan Ryan: declan.ryan@northampton.ac.uk
26 Esme Tuttiett: ertuttiett1@sheffield.ac.uk
27 Mark Faghy: m.faghy@derby.ac.uk

28

29 Corresponding author:

30 Dr Ruth Ashton
31 Human Sciences Research Centre
32 University of Derby
33 Kedleston Road Campus
34 DE22 1GB

35

36 Conflict of interest statement:

37 The authors declare no conflicts of interest.

38

1 **Abstract**

2 SARS-CoV-2 (COVID-19) transmission continues to impact people globally. Whilst the
3 acute symptoms and management strategies are well documented, millions of people
4 globally are experiencing a prolonged and debilitating symptom profile that is reported
5 to last months and even years. COVID-19 is a multi-system disease however the
6 magnitude of the effects and its associated legacy is presently not well understood.
7 Early reports indicate that multidisciplinary approaches between clinical and non-
8 clinical entities are needed to provide effective and rehabilitative patient support
9 pathways and restore pre-COVID-19 quality of life and functional status. Accordingly,
10 this review provides a summary of the impact on cardiovascular, inflammatory,
11 respiratory, and musculoskeletal function following an acute COVID-19 infection along
12 with the prolonged effects of long-COVID.

13

14 **Key words:** COVID-19, long-COVID, cardiorespiratory, cardiometabolic, recovery,
15 rehabilitation

1 **Introduction**

2 Severe Acute Respiratory Syndrome coronavirus type-2 (SARS-CoV-2) is a novel
3 coronavirus that surfaced in late 2019. The virus resulted in a worldwide pandemic of
4 a disease named by the World Health Organisation (WHO) as COVID-19. The COVID-
5 19 pandemic continues to infect many people worldwide with extreme symptoms now
6 being well documented [1-4]. However, the long-term effects on those infected by the
7 virus remain largely unknown. Whilst a series of longitudinal investigations are
8 underway to increase the knowledge and understanding, reports highlight that
9 sustained transmission and emerging variants continue to cause global challenges to
10 healthcare providers. Currently, it is estimated that of those infected with COVID-19 in
11 the UK, one in ten people will experience prolonged symptoms lasting months to years
12 including fatigue, breathlessness, neurological deconditioning [5]. These effects are
13 referred to as Post-Acute Sequelae of SARS-CoV-2 infection colloquially termed 'long-
14 COVID' with the magnitude and the associated legacy impacts and the burden to
15 population health and wellbeing being presently not understood in its entirety. Whilst
16 the authors acknowledge the evident and documented favourable female sex bias in
17 COVID-19 infection and severity, the need to understand the mechanisms and causal
18 relationships (e.g., comorbidities and underlying health status) requires further
19 investigation [6] and is outside of the scope of this current review.

20 **Cardiovascular Function**

21 Initially, COVID-19 was thought to primarily be an acute respiratory distress syndrome
22 (ARDS) however, it has since become clear that COVID-19 is in fact a multiple organ
23 disease. Cardiovascular disease (CVD) remains the leading cause of morbidity and
24 mortality globally [7] and medication prescribed to reduce the risk of CVD could
25 increase the susceptibility to or the severity of a COVID-19 infection [8]. It also appears
26 that COVID-19 infection can promote cardiovascular disorders. The virus enters host
27 cells through the binding of the spike protein to Angiotensin converting enzyme 2
28 (ACE-2) on pulmonary epithelial cells causing damage to the lungs (6, 7) as well as
29 directly binding to vascular endothelial cells of other organs, such as the kidneys and
30 heart [9, 10]. It is possible that, due to the mediating effects of ACE-2 on blood
31 pressure, those with hypertension could have some dysregulation of ACE-2 function
32 therefore predisposing individuals to severe conditions and mortality [11]. It has also
33 been suggested that the occurrence of cardiovascular events in those with COVID-19

1 is caused by inflammation and vascular remodelling brought about by endothelial
2 dysfunction [9, 12]. Such dysfunction is due to 'cytokine and coagulation storms' that
3 can compromise the integrity and physiological anti-thrombotic and anti-inflammatory
4 properties of the endothelium within vessels [13].

5 Data suggests an increased risk of severe complications and mortality in those who
6 contract COVID-19 with pre-existing CVD or who present with one or more risk factors
7 such as hypertension, diabetes mellitus, hypercholesterolaemia, or obesity [14-16].
8 For example, a meta-analysis performed in China suggested that mortality in those
9 with pre-existing CVD and infected with COVID-19 was around 11%[17]. In addition,
10 a report of 393 patients hospitalised with COVID-19 in the USA demonstrated that
11 ~50% of patients had underlying hypertension (54% of ventilated patients), 36% were
12 obese (43% of ventilated patients), 25% had diabetes mellitus (28% of ventilated
13 patients) and 14% were diagnosed with coronary artery disease (19% of ventilated
14 patients) [18]. The high prevalence of obesity amongst those hospitalised with COVID-
15 19 reported here was also deemed to be a considerable risk factor for respiratory
16 failure, prompting the need for mechanical ventilation.

17 It appears that a COVID-19 infection promotes the development of cardiovascular
18 disorders including myocardial injury, myocarditis, arrhythmias, acute coronary
19 syndrome, and venous thromboembolism [8, 13, 14, 19]. Elevated cardiac troponin
20 (cTn) levels are evident in 8-62% of hospitalised patients with COVID-19 and are
21 suggestive of myocardial injury alongside being associated with greater disease
22 severity, need for mechanical ventilation, and mortality [19-22]. Along with biomarker
23 evidence, echocardiographic abnormalities are also commonly reported. Such
24 abnormalities include right ventricular dysfunction (26.3%), left ventricular wall motion
25 abnormalities (23.7%), global left ventricular dysfunction (18.4%), diastolic dysfunction
26 (13.2%), and pericardial effusion (7.2%) [21]. In addition, it appears that coronary
27 artery calcium and total thoracic calcium obtained via chest computed tomography
28 (CT) on admission of COVID-19 patients in hospital, could be used to help with risk
29 stratification and help assess patients' mortality risk [23]. It has been suggested that
30 drugs such as canakinumab, previously used as an interleukin-1 β blocking agent in
31 cancer patients, can significantly reduce mortality rate and CVD in patients deemed to
32 be at a higher risk of mortality [24].

1 The severity, extent, and long-term cardiovascular effects of COVID-19 and its
2 treatments are yet to be understood entirely. However, there is evidence of
3 cardiovascular involvement post-COVID-19 infection. Puntmann et al [25] reported
4 cardiac involvement in 78%, and ongoing inflammation in 60% of patients (n=100) in
5 the months following COVID-19 infection. It was also evident that various cardiac
6 symptoms were common with atypical chest pain (17%), palpitations (20%), and
7 dyspnoea and exhaustion (36%) all being reported [25]. For those with CVD, long-
8 COVID is of concern due to its association with high morbidity and exacerbation of
9 underlying cardiovascular disorders. Studies examining patients with long-COVID
10 have reported dyspnoea, joint pain and muscle weakness, chest pain, sleep difficulties
11 and reduced quality of life [26, 27]. What remains unclear, is the link between cardiac
12 involvement and insult as a result of a COVID-19 infection and the symptoms evident
13 in those with long COVID.

14 ***Blood Biomarkers***

15 The clustering of cardiovascular risk factors (hyperglycaemia, obesity, dyslipidaemia,
16 and hypertension) is termed metabolic syndrome [28]. Although the presence of these
17 components is associated with adverse outcomes of COVID-19 [29-36], there is
18 limited evidence on the risk of long-term complications, with most finding no increased
19 risk of long-covid [37-39]. Conversely, infection with COVID-19 does appear to
20 increase the risk of future development of cardio-metabolic issues such as myocardial
21 inflammation and substantial impairment within multiple organs (e.g., lungs, liver,
22 pancreas) [25, 40-42].

23 The components of metabolic syndrome can stimulate the dysregulation of the Renin-
24 Angiotensin-Aldosterone System, modulated by ACE-2, leading to an increased
25 presence of Angiotensin II. The binding of Angiotensin II to Angiotensin II type I
26 receptors can be a stimulus for cardiovascular insult, such as endothelial dysfunction,
27 thrombosis, chronic inflammation [19, 43]. COVID-19 binds to ACE-2 [44] and enters
28 cells via ACE-2 receptors present on the cells of multiple organs [45]. The
29 cardioprotective role of ACE-2, and the binding of COVID-19 to ACE-2, has created
30 uncertainties in the susceptibility to COVID-19 in patients prescribed ACE inhibitors,
31 [46] whilst suggestions of pharmaceutical discontinuation should not be made without
32 evidence of an increased risk of infection in this population [47]. That being said, a
33 study by Wang and colleagues suggests that ACE inhibitors are safe for COVID-19

1 patients and can also help in the treatment of COVID-19 induced pneumonia and can
2 be used in line with relevant guidance [48]. The influence of Angiotensin II on COVID-
3 19 severity has been demonstrated in a cross-sectional study that evidenced higher
4 concentrations of Angiotensin II in critically-ill COVID-19 patients, in comparison to
5 mildly-ill and controls [49]. In populations with components of metabolic syndrome, the
6 concentration of Angiotensin II is elevated and the subsequent elevation of
7 Angiotensin II due to COVID-19 infection will likely exacerbate cardiovascular,
8 respiratory, and metabolic complications [50].

9 COVID-19 stimulates an inflammatory response with interleukin-6 (IL-6), C-reactive
10 protein (CRP), and tumour necrosis factor-alpha (TNF- α) [51-54]. The chronic
11 presence of IL-6 and TNF- α within the endothelium stimulates vascular smooth muscle
12 cell migration from the Media to the Intima [55, 56], contributing to arterial wall
13 thickening and atherosclerotic plaque formation. Furthermore, the maximum value of
14 IL-6 and CRP have predicted respiratory failure [57]. On 6th July 2021, the World
15 Health Organisation updated its patient care guideline to include IL-6 receptor blockers
16 for severely or critically ill COVID-19 patients [58] as administration of these drugs
17 reduces the need for mechanical ventilation (30 fewer per 1000 patients), length of
18 hospital stay (4.3 days fewer), but the association with mortality was less clear (15
19 fewer per 1000 patients) [59].

20 It appears that pre-existing metabolic syndrome components do not appear to be
21 predictors of long-COVID, but the SARS-CoV-2 infection does appear to increase the
22 risk of future cardiometabolic complications. It seems that part of the pathophysiology
23 surrounding this increased risk of future cardiometabolic issues could be due to the
24 disruption in the Renin-Angiotensin-Aldosterone System and systemic inflammatory
25 responses. Further longitudinal research will be required to determine the need and
26 efficacy of (non)pharmaceutical intervention to manage cardiometabolic implications
27 of COVID-19 infection [60].

28 ***Respiratory Function***

29 The respiratory system is the front-line of the COVID-19 infection, with the respiratory
30 tract epithelium the key entry point upon inhalation [61]. The respiratory symptoms
31 and outcomes of COVID-19 are diverse, with many displaying mild upper respiratory
32 tract symptoms, however, some patients develop more severe illness, commonly viral

1 pneumonia, leading to ARDS relating to poor health outcomes and/or mortality [62].
2 Data on the short-term respiratory sequelae is still emerging, and longer-term follow-
3 up studies remain scarce. However, from the limited available data, 188 patients (from
4 1370 pulmonary CT scans) identified the presence of pleural effusion which was linked
5 to increased risk of cardio-respiratory complications and in hospital mortality [63].
6 Whilst more detailed investigations and cohort analysis are needed, the presence of
7 pulmonary effusion in hospitalized patients, might serve as an clinical indicator to
8 COVID-19 severity and post-COVID-19 outcomes. Early data, and that from previous
9 coronavirus outbreaks, indicates that long-term respiratory complications and a
10 profound and complex symptomology are likely to persist in some patients [64].

11 Current evidence on the acute effects of COVID-19 shows reduced pulmonary
12 diffusing capacity (DLco) as the key impairment following infection. This is largely
13 associated with disease severity, with abnormally low DLco (<80% predicted) reported
14 in approximately 60% of patients with severe disease, 32% in moderate disease and
15 20% in mild disease [65]. COVID-19 appears to have little impact on spirometry
16 measures, with lung volumes close to normative values, particularly in those with
17 milder disease [66]. At 3 months post-infection, chronic dyspnoea is reported in
18 approximately half of the patients and is associated with greater restriction on
19 spirometry, lower DLco, reduced functional capacity and greater desaturation during
20 exertion, compared to those without persistent dyspnoea [67], suggestive of an
21 underlying physiological mechanism that is responsible for this.

22 As the pandemic ensues, studies looking at the longer-term (>3 months) implications
23 of COVID-19 are beginning to emerge [26, 68, 69]. The UK-based multi-centre
24 PHOSP-COVID study [60, 69] concluded that 5-months post-hospitalisation, recovery
25 was only 29%, with 94% of patients experiencing prolonged symptom profiles. At 6
26 months, studies have shown that impaired DLco (<80%) persists, with low DLco
27 present in 30-55% of patients [26, 68, 69]. However, significant improvements in DLco
28 have been shown 6-12 months post-hospitalisation, with evidence that women are at
29 higher risk of persistent lung diffusion impairment [68]. In this 12-month follow-up
30 study, exercise capacity improved significantly over time, however persistent
31 physiological and CT scan abnormalities were evident in a sub-group of patients.
32 Persistent radiological abnormalities included interstitial thickening and reticular
33 opacity, suggestive of evolving fibrosis [68]. Experience from MERS and SARS-CoV-

1 1 indicates that fibrotic disease may be an outcome of concern from COVID-19 [70].
2 Evidence from SARS-CoV-1 showed that 4.6% of patients had interstitial lung
3 abnormalities at 15 years, with the greatest recovery from interstitial lung damage
4 occurring within the first two years following infection [71].

5 The extent of pulmonary function and physical impairment following COVID-19
6 remains unclear. In addition to the paucity of long-term follow-up data following
7 COVID-19 infection, most data report the health consequences of hospitalised
8 individuals, thus more research on long-COVID and in non-hospitalised individuals is
9 crucial [72] to inform and meet the broad needs of patients and to mitigate against the
10 impending impact upon healthcare systems, the economy and society.

11 ***Skeletal Muscle***

12 It is important to recognise the integrative pathophysiological processes following
13 COVID-19 infection and subsequent long-COVID. Cardiorespiratory fitness is a key
14 predictor of functional capacity, quality of life, and a strong predictor of mortality [73,
15 74]. Aerobic capacity, quantified by maximal oxygen consumption (VO_{2peak}), and
16 ventilatory efficiency, is quantified by the minute ventilation/carbon dioxide production
17 (VE/VCO_2) slope, are two established measures obtained through cardio-pulmonary
18 exercise testing and several initial studies to date have reported the impact of COVID-
19 19 on both [75]. Indeed, at discharge from hospitalisation, VO_{2peak} is impaired in
20 COVID patients, which has been attributed to a peripheral oxygen extraction limitation,
21 rather than central impairment [76]. Similarly, investigations at 3 months [77] and 11
22 months post-hospitalisation [78] have shown impaired VO_{2peak} and early attainment of
23 ventilatory threshold alongside 'normal' pulmonary function. It is well-established that
24 VO_{2peak} is determined by the delivery and utilisation of oxygen [79]. The latter depends
25 on factors within the periphery that mediate the pathway of oxygen from haemoglobin
26 to mitochondria, as well as mitochondrial function itself [80]. Long-COVID symptoms
27 could be underpinned by dysfunction in the pathway of oxygen from the blood to
28 mitochondria [75]. Strategies are needed to augment impaired physiological
29 processes and also require detailed investigation. Cardiovascular exercise is known
30 to be a potent stimulus for mitochondrial biogenesis and improving mitochondrial
31 function [81]. The optimal prescription and inclusion of exercise in long-COVID
32 patients must be considered with the balance of factors such as reduced exercise

1 capacity and tolerance as well as post-exertional malaise [82]. As highlighted by
2 Twomey et al.,[82] and enforced here, exercise is not the route to recovery for all
3 patients in other diseases, such as cancer or chronic fatigue syndrome; therefore,
4 careful consideration and appropriate measures should be taken when prescribing
5 exercise as a rehabilitative tool in long-COVID patients.

6 The hyperinflammatory state and altered cardio-respiratory function result in
7 excessive fatigue or post-exertional malaise that is being reported in patients with
8 long-COVID. In conditions where post-exertional malaise and excessive fatigue are
9 characteristics such as myalgic encephalomyelitis (ME)/chronic fatigue syndrome
10 (CFS), there is a demonstrable reduction in VO_{2peak} in the days following testing with
11 an altered metabolic [83] and inflammatory response to exercise observed [84, 85].
12 There is a strong link between ME/CFS and autonomic nervous system abnormalities.
13 The autonomic nervous system plays a vital role in the regulation of the whole-body
14 homeostasis and so any disruption can have a significant effect on multiple bodily
15 systems[86]. There is some evidence to suggest that long-COVID may also include
16 autonomic dysfunction therefore aggravating some cardio-respiratory and metabolic
17 complications therefore supporting the multi-system nature of COVID-19 [86, 87].A
18 shift in energy system contribution to ATP resynthesis is common in viral infections
19 [88], with an increased rate of glycolysis and downregulation of oxidative
20 phosphorylation typically observed [89]. Impaired oxidative phosphorylation likely
21 occurs during the acute COVID-19 infection period. During exercise, this can lead to
22 the accumulation of deleterious metabolites which impair the contractile function of
23 skeletal muscle, but additionally, a shift in the inflammatory status of muscle. There is
24 a need to increase mechanistic insight into mitochondrial (dys)function in long COVID
25 to test this hypothesis although, it does seem to be the case in other diseases with
26 similar symptomatology such as ME [83].

27 COVID-19 induces a systemic hyperinflammatory state causing multi-organ damage
28 via the 'cytokine storm' [90, 91]. In addition, viral infections increase mitochondrial
29 production of reactive oxygen species and suppress endogenous anti-oxidant systems
30 [92]. Combined, this hyperinflammatory state leads to cachexia and sarcopenia [93,
31 94]. The resulting loss of muscle tissue alongside disuse atrophy results in premature
32 loss of muscle strength impeding physical function and potentially future
33 independence of patients with long-COVID. Taking approaches from combating age-

1 related and disease-related muscle atrophy (e.g., nutrition and exercise) could provide
2 beneficial adaptations in preventing neuromuscular decline. The National Institute for
3 Health Care and Excellence (NICE) recommends that following COVID-19 infection,
4 initiating progressive rehabilitation programmes within the 30 days will lead to optimal
5 impacts and enhancement of recovery [95]. These programmes should be
6 multidisciplinary and holistic, but with respect to enhancing musculoskeletal health,
7 should primarily focus on rectifying any muscle atrophy that has occurred with
8 consideration to excessive fatigue or post-exertional malaise [45, 74].

9 **Conclusion**

10 The results of observational studies highlight that long-COVID patients report
11 persistent and debilitating symptoms that impact recovery, quality of life and broader
12 economic and social activities [96]. A recent scoping review reports that patients
13 highlighted >100 different symptoms with varying severity [97] broadly defined in the
14 areas of cardiovascular [98], pulmonary [99] and respiratory [26], pain [100], fatigue
15 [101], psychological and cognitive disorders [102], sensory impairment [103],
16 functional impairment [104] alongside general infection symptoms (e.g. nausea and
17 fever). Whilst these studies have identified commonly reported symptoms, it is clear
18 that patient experiences are broad and there is a need for longitudinal approaches to
19 determine the prevalence and fluctuation of symptom exacerbation. The information
20 obtained from such approaches should be used in conjunction with the lived
21 experiences of patients in the design and development of COVID-19 specific support
22 pathways that are developed using a non-pharmacological and rehabilitative basis that
23 can be used to restore pre-COVID-19 functional status.

24 What is increasingly apparent is that multiple agencies will need to come together in
25 interdisciplinary approaches to support long-COVID patients. To be effective the
26 patient support pathways will undoubtedly be as complex as the symptomology,
27 creating a unique challenge for clinical (e.g., primary care) and non-clinical entities
28 (e.g., community health services and academic research institutions) to work
29 collaboratively in the interest of improved patient outcomes. With long-COVID affecting
30 ~57% of confirmed cases in the 6-months post-infection [105], pressure on clinical
31 services will continue to grow with a broad impact upon all clinical areas. In a previous
32 paper, the role and importance of utilising complementary expertise, knowledge and

1 resource from sports medicine and the exercise sciences were highlighted [106, 107].
2 As the prevalence of long-COVID increases globally and the need for complex and
3 multi-faceted support pathways is apparent. There is undoubtedly a need to look at
4 broader opportunities to facilitate service delivery and address existing and
5 longstanding issues with morbidity and functional capacity.

6

7 *Author Contributions*

8 All authors contributed to the writing and editorial changes in the manuscript. All
9 authors read and approved the final manuscript.

10

11 *Acknowledgements*

12 We would like to express our gratitude to all those who helped us during the writing of
13 this manuscript. Thanks to all the peer reviewers for their opinions and suggestions.

14

15 *Ethics Approval and Consent to Participate*

16 Not Applicable.

17

18 *Funding*

19 This research received no external funding.

1 References

- 2 1. Chen, N., et al., *Epidemiological and clinical characteristics of 99 cases of 2019 novel*
3 *coronavirus pneumonia in Wuhan, China: a descriptive study*. The Lancet, 2020. **395**(10223):
4 p. 507-513.
- 5 2. Huang, C., et al., *Clinical features of patients infected with 2019 novel coronavirus in Wuhan,*
6 *China*. The Lancet, 2020. **395**(10223): p. 497-506.
- 7 3. Wang, D., et al., *Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel*
8 *Coronavirus–Infected Pneumonia in Wuhan, China*. JAMA, 2020. **323**(11): p. 1061-1069.
- 9 4. Zhu, N., et al., *A Novel Coronavirus from Patients with Pneumonia in China, 2019*. New
10 England Journal of Medicine, 2020. **382**(8): p. 727-733.
- 11 5. Mahase, E., *Covid-19: What do we know about "long covid"?* Bmj, 2020. **370**: p. m2815.
- 12 6. Cereda, A., et al., *The hidden interplay between sex and COVID-19 mortality: the role of*
13 *cardiovascular calcification*. GeroScience, 2021. **43**(5): p. 2215-2229.
- 14 7. *World Health Organization cardiovascular disease risk charts: revised models to estimate risk*
15 *in 21 global regions*. Lancet Glob Health, 2019. **7**(10): p. e1332-e1345.
- 16 8. Nishiga, M., et al., *COVID-19 and cardiovascular disease: from basic mechanisms to clinical*
17 *perspectives*. Nature Reviews Cardiology, 2020. **17**(9): p. 543-558.
- 18 9. Liu, H., et al., *Thrombosis and Coagulopathy in COVID-19: Current Understanding and*
19 *Implications for Antithrombotic Treatment in Patients Treated With Percutaneous Coronary*
20 *Intervention*. Frontiers in Cardiovascular Medicine, 2021. **7**(378).
- 21 10. Lu, R., et al., *Genomic characterisation and epidemiology of 2019 novel coronavirus:*
22 *implications for virus origins and receptor binding*. Lancet, 2020. **395**(10224): p. 565-574.
- 23 11. Del Turco, S., et al., *COVID-19 and cardiovascular consequences: Is the endothelial*
24 *dysfunction the hardest challenge?* Thrombosis research, 2020. **196**: p. 143-151.
- 25 12. Deanfield, J.E., J.P. Halcox, and T.J. Rabelink, *Endothelial function and dysfunction: testing*
26 *and clinical relevance*. Circulation, 2007. **115**(10): p. 1285-95.
- 27 13. Zheng, Y.Y., et al., *COVID-19 and the cardiovascular system*. Nat Rev Cardiol, 2020. **17**(5): p.
28 259-260.
- 29 14. Cenko, E., et al., *Cardiovascular disease and COVID-19: a consensus paper from the ESC*
30 *Working Group on Coronary Pathophysiology & Microcirculation, ESC Working Group*
31 *on Thrombosis and the Association for Acute CardioVascular Care (ACVC), in collaboration*
32 *with the European Heart Rhythm Association (EHRA)*. Cardiovascular Research, 2021.
- 33 15. Madjid, M., et al., *Potential Effects of Coronaviruses on the Cardiovascular System: A Review*.
34 JAMA Cardiol, 2020. **5**(7): p. 831-840.
- 35 16. Clerkin, K.J., et al., *COVID-19 and Cardiovascular Disease*. Circulation, 2020. **141**(20): p. 1648-
36 1655.
- 37 17. The Novel Coronavirus Pneumonia Emergency Response Epidemiology, T., *The*
38 *Epidemiological Characteristics of an Outbreak of 2019 Novel Coronavirus Diseases (COVID-*
39 *19) - China, 2020*. China CDC weekly, 2020. **2**(8): p. 113-122.
- 40 18. Goyal, P., et al., *Clinical Characteristics of Covid-19 in New York City*. N Engl J Med, 2020.
41 **382**(24): p. 2372-2374.
- 42 19. Chung, M.K., et al., *COVID-19 and Cardiovascular Disease*. Circulation Research, 2021.
43 **128**(8): p. 1214-1236.
- 44 20. Sandoval, Y., J.L. Januzzi, Jr., and A.S. Jaffe, *Cardiac Troponin for Assessment of Myocardial*
45 *Injury in COVID-19: JACC Review Topic of the Week*. J Am Coll Cardiol, 2020. **76**(10): p. 1244-
46 1258.
- 47 21. Giustino, G., et al., *Characterization of Myocardial Injury in Patients With COVID-19*. J Am
48 Coll Cardiol, 2020. **76**(18): p. 2043-2055.
- 49 22. Shi, S., et al., *Association of Cardiac Injury With Mortality in Hospitalized Patients With*
50 *COVID-19 in Wuhan, China*. JAMA Cardiol, 2020. **5**(7): p. 802-810.

- 1 23. Giannini, F., et al., *Coronary and total thoracic calcium scores predict mortality and provides*
2 *pathophysiologic insights in COVID-19 patients.* Journal of cardiovascular computed
3 tomography, 2021. **15**(5): p. 421-430.
- 4 24. Quagliariello, V., et al., *Interleukin-1 blocking agents as promising strategy for prevention of*
5 *anticancer drug-induced cardiotoxicities: possible implications in cancer patients with COVID-*
6 *19.* European Reviews for Medical and Pharmacological Sciences, 2021. **25**(21): p. 6797-
7 6812.
- 8 25. Puntmann, V.O., et al., *Outcomes of Cardiovascular Magnetic Resonance Imaging in Patients*
9 *Recently Recovered From Coronavirus Disease 2019 (COVID-19).* JAMA Cardiology, 2020.
10 **5**(11): p. 1265-1273.
- 11 26. Huang, C., et al., *6-month consequences of COVID-19 in patients discharged from hospital: a*
12 *cohort study.* The Lancet, 2021. **397**(10270): p. 220-232.
- 13 27. Carfi, A., R. Bernabei, and F. Landi, *Persistent Symptoms in Patients After Acute COVID-19.*
14 *Jama*, 2020. **324**(6): p. 603-605.
- 15 28. Huang, P.L., *A comprehensive definition for metabolic syndrome.* Dis Model Mech, 2009. **2**(5-
16 6): p. 231-7.
- 17 29. Li, X., et al., *Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan.* J
18 *Allergy Clin Immunol*, 2020. **146**(1): p. 110-118.
- 19 30. Zheng, Z., et al., *Risk factors of critical & mortal COVID-19 cases: A systematic literature*
20 *review and meta-analysis.* J Infect, 2020. **81**(2): p. e16-e25.
- 21 31. Yang, J., J. Hu, and C. Zhu, *Obesity aggravates COVID-19: A systematic review and meta-*
22 *analysis.* J Med Virol, 2021. **93**(1): p. 257-261.
- 23 32. Chen, T., et al., *Clinical characteristics of 113 deceased patients with coronavirus disease*
24 *2019: retrospective study.* BMJ, 2020. **368**: p. m1091.
- 25 33. Zhou, F., et al., *Clinical course and risk factors for mortality of adult inpatients with COVID-19*
26 *in Wuhan, China: a retrospective cohort study.* The Lancet, 2020. **395**(10229): p. 1054-1062.
- 27 34. Wang, S.Y., et al., *Association of obesity with venous thromboembolism and myocardial*
28 *injury in COVID-19.* *Obes Res Clin Pract*, 2021. **15**(5): p. 512-514.
- 29 35. Yates, T., et al., *Obesity, Ethnicity, and Covid-19 Mortality: A population-based cohort study*
30 *of 12.6 Million Adults in England.* medRxiv, 2021: p. 2021.07.22.21260416.
- 31 36. Yates, T., et al., *Obesity, chronic disease, age, and in-hospital mortality in patients with covid-*
32 *19: analysis of ISARIC clinical characterisation protocol UK cohort.* BMC Infectious Diseases,
33 2021. **21**(1): p. 717.
- 34 37. Hirschtick, J.L., et al., *Population-based estimates of post-acute sequelae of SARS-CoV-2*
35 *infection (PASC) prevalence and characteristics.* Clin Infect Dis, 2021.
- 36 38. Peghin, M., et al., *Post-COVID-19 symptoms 6 months after acute infection among*
37 *hospitalized and non-hospitalized patients.* Clin Microbiol Infect, 2021. **27**(10): p. 1507-1513.
- 38 39. Sudre, C.H., et al., *Attributes and predictors of long COVID.* Nature Medicine, 2021. **27**(4): p.
39 626-631.
- 40 40. Rudski, L., et al., *Multimodality Imaging in Evaluation of Cardiovascular Complications in*
41 *Patients With COVID-19: JACC Scientific Expert Panel.* J Am Coll Cardiol, 2020. **76**(11): p.
42 1345-1357.
- 43 41. Dennis, A., et al., *Multiorgan impairment in low-risk individuals with post-COVID-19*
44 *syndrome: a prospective, community-based study.* BMJ Open, 2021. **11**(3): p. e048391.
- 45 42. Farshidfar, F., N. Koleini, and H. Ardehali, *Cardiovascular complications of COVID-19.* JCI
46 *Insight*, 2021. **6**(13).
- 47 43. Samavati, L. and B.D. Uhal, *ACE2, Much More Than Just a Receptor for SARS-COV-2.* Frontiers
48 *in Cellular and Infection Microbiology*, 2020. **10**(317).
- 49 44. Wan, Y., et al., *Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis*
50 *Based on Decade-Long Structural Studies of SARS Coronavirus.* Journal of Virology, 2020.
51 **94**(7): p. e00127-20.

- 1 45. Crook, H., et al., *Long covid—mechanisms, risk factors, and management*. BMJ, 2021. **374**: p.
2 n1648.
- 3 46. Fang, L., G. Karakiulakis, and M. Roth, *Antihypertensive drugs and risk of COVID-19?*
4 *– Authors' reply*. The Lancet Respiratory Medicine, 2020. **8**(5): p. e32-e33.
- 5 47. Brown, J.D., *Antihypertensive drugs and risk of COVID-19?* The Lancet Respiratory Medicine,
6 2020. **8**(5): p. e28.
- 7 48. Wang, W., et al., *Angiotensin-converting enzyme inhibitors (ACEI) or angiotensin receptor*
8 *blockers (ARBs) may be safe for COVID-19 patients*. BMC Infectious Diseases, 2021. **21**(1): p.
9 114.
- 10 49. Wu, Z., et al., *Elevation of plasma angiotensin II level is a potential pathogenesis for the*
11 *critically ill COVID-19 patients*. Critical Care, 2020. **24**(1): p. 290.
- 12 50. Tseng, Y.H., R.C. Yang, and T.S. Lu, *Two hits to the renin-angiotensin system may play a key*
13 *role in severe COVID-19*. Kaohsiung J Med Sci, 2020. **36**(6): p. 389-392.
- 14 51. Ahnach, M., et al., *C-reactive protein as an early predictor of COVID-19 severity*. Journal of
15 medical biochemistry, 2020. **39**(4): p. 500-507.
- 16 52. Chen, L.Y.C., et al., *Confronting the controversy: interleukin-6 and the COVID-19 cytokine*
17 *storm syndrome*. The European respiratory journal, 2020. **56**(4): p. 2003006.
- 18 53. Leisman, D.E., et al., *Cytokine elevation in severe and critical COVID-19: a rapid systematic*
19 *review, meta-analysis, and comparison with other inflammatory syndromes*. The Lancet
20 Respiratory Medicine, 2020. **8**(12): p. 1233-1244.
- 21 54. Smilowitz, N.R., et al., *C-reactive protein and clinical outcomes in patients with COVID-19*.
22 European Heart Journal, 2021. **42**(23): p. 2270-2279.
- 23 55. Newman, W.H., et al., *Cyclic AMP inhibits production of interleukin-6 and migration in*
24 *human vascular smooth muscle cells*. J Surg Res, 2003. **109**(1): p. 57-61.
- 25 56. Ciccone, M.M., et al., *Correlation between inflammatory markers of atherosclerosis and*
26 *carotid intima-media thickness in Obstructive Sleep Apnea*. Molecules, 2014. **19**(2): p. 1651-
27 62.
- 28 57. Herold, T., et al., *Elevated levels of IL-6 and CRP predict the need for mechanical ventilation*
29 *in COVID-19*. J Allergy Clin Immunol, 2020. **146**(1): p. 128-136.e4.
- 30 58. Organization, W.H. *WHO recommends life-saving interleukin-6 receptor blockers for COVID-*
31 *19 and urges producers to join efforts to rapidly increase access, WHO*. 2021; Available from:
32 [https://www.who.int/news/item/06-07-2021-who-recommends-life-saving-interleukin-6-](https://www.who.int/news/item/06-07-2021-who-recommends-life-saving-interleukin-6-receptor-blockers-for-covid-19-and-urges-producers-to-join-efforts-to-rapidly-increase-access)
33 [receptor-blockers-for-covid-19-and-urges-producers-to-join-efforts-to-rapidly-increase-](https://www.who.int/news/item/06-07-2021-who-recommends-life-saving-interleukin-6-receptor-blockers-for-covid-19-and-urges-producers-to-join-efforts-to-rapidly-increase-access)
34 [access](https://www.who.int/news/item/06-07-2021-who-recommends-life-saving-interleukin-6-receptor-blockers-for-covid-19-and-urges-producers-to-join-efforts-to-rapidly-increase-access).
- 35 59. Siemieniuk, R.A., et al., *Drug treatments for covid-19: living systematic review and network*
36 *meta-analysis*. BMJ, 2020. **370**: p. m2980.
- 37 60. Evans, R.A., et al., *Clinical characteristics with inflammation profiling of Long-COVID and*
38 *association with one-year recovery following hospitalisation in the UK: a prospective*
39 *observational study*. medRxiv, 2021: p. 2021.12.13.21267471.
- 40 61. Brosnahan, S.B., et al., *COVID-19 and Respiratory System Disorders*. Arteriosclerosis,
41 Thrombosis, and Vascular Biology, 2020. **40**(11): p. 2586-2597.
- 42 62. Wang, F., R.M. Kream, and G.B. Stefano, *Long-Term Respiratory and Neurological Sequelae*
43 *of COVID-19*. Med Sci Monit, 2020. **26**: p. e928996.
- 44 63. Cereda, A., et al., *Is pleural effusion in COVID-19 interstitial pneumonia related to in-hospital*
45 *mortality?* Italian Journal of Medicine, 2021. **15**(1).
- 46 64. Zhu, Z., et al., *From SARS and MERS to COVID-19: a brief summary and comparison of severe*
47 *acute respiratory infections caused by three highly pathogenic human coronaviruses*.
48 Respiratory Research, 2020. **21**(1): p. 224.
- 49 65. Thomas, M., O.J. Price, and J.H. Hull, *Pulmonary function and COVID-19*. Current Opinion in
50 Physiology, 2021. **21**: p. 29-35.

- 1 66. Froidure, A., et al., *Integrative respiratory follow-up of severe COVID-19 reveals common*
2 *functional and lung imaging sequelae*. Respiratory medicine, 2021. **181**: p. 106383-106383.
- 3 67. Cortés-Telles, A., et al., *Pulmonary function and functional capacity in COVID-19 survivors*
4 *with persistent dyspnoea*. Respir Physiol Neurobiol, 2021. **288**: p. 103644.
- 5 68. Wu, X., et al., *3-month, 6-month, 9-month, and 12-month respiratory outcomes in patients*
6 *following COVID-19-related hospitalisation: a prospective study*. The Lancet Respiratory
7 Medicine, 2021. **9**(7): p. 747-754.
- 8 69. Group, P.-C.C., et al., *Physical, cognitive and mental health impacts of COVID-19 following*
9 *hospitalisation – a multi-centre prospective cohort study*. medRxiv, 2021: p.
10 2021.03.22.21254057.
- 11 70. McDonald, L.T., *Healing after COVID-19: are survivors at risk for pulmonary fibrosis?*
12 American journal of physiology. Lung cellular and molecular physiology, 2021. **320**(2): p.
13 L257-L265.
- 14 71. Zhang, P., et al., *Long-term bone and lung consequences associated with hospital-acquired*
15 *severe acute respiratory syndrome: a 15-year follow-up from a prospective cohort study*.
16 Bone Research, 2020. **8**(1): p. 8.
- 17 72. Augustin, M., et al., *Post-COVID syndrome in non-hospitalised patients with COVID-19: a*
18 *longitudinal prospective cohort study*. The Lancet Regional Health – Europe, 2021. **6**.
- 19 73. Strasser, B. and M. Burtscher, *Survival of the fittest: VO(2)max, a key predictor of longevity?*
20 Front Biosci (Landmark Ed), 2018. **23**: p. 1505-1516.
- 21 74. Faghy, M.A., et al., *Cardiopulmonary exercise testing in the COVID-19 endemic phase*. British
22 journal of anaesthesia, 2020. **125**(4): p. 447-449.
- 23 75. Arena, R. and M.A. Faghy, *Cardiopulmonary exercise testing as a vital sign in patients*
24 *recovering from COVID-19*. Expert Review of Cardiovascular Therapy, 2021. **19**(10): p. 877-
25 880.
- 26 76. Baratto, C., et al., *Impact of COVID-19 on exercise pathophysiology: a combined*
27 *cardiopulmonary and echocardiographic exercise study*. J Appl Physiol (1985), 2021. **130**(5):
28 p. 1470-1478.
- 29 77. Rinaldo, R.F., et al., *Deconditioning as main mechanism of impaired exercise response in*
30 *COVID-19 survivors*. European Respiratory Journal, 2021: p. 2100870.
- 31 78. Singh, J., et al., *SARS-CoV-2 variants of concern are emerging in India*. Nature Medicine,
32 2021. **27**(7): p. 1131-1133.
- 33 79. Wagner, P.D., *Determinants of maximal oxygen transport and utilization*. Annu Rev Physiol,
34 1996. **58**: p. 21-50.
- 35 80. Wagner, P.D., *Gas exchange and peripheral diffusion limitation*. Med Sci Sports Exerc, 1992.
36 **24**(1): p. 54-8.
- 37 81. Granata, C., N.A. Jamnick, and D.J. Bishop, *Principles of Exercise Prescription, and How They*
38 *Influence Exercise-Induced Changes of Transcription Factors and Other Regulators of*
39 *Mitochondrial Biogenesis*. Sports Medicine, 2018. **48**(7): p. 1541-1559.
- 40 82. Twomey, R., et al., *Chronic fatigue and post-exertional malaise in people living with long*
41 *COVID*. medRxiv, 2021: p. 2021.06.11.21258564.
- 42 83. Rutherford, G., P. Manning, and J.L. Newton, *Understanding Muscle Dysfunction in Chronic*
43 *Fatigue Syndrome*. Journal of Aging Research, 2016. **2016**: p. 2497348.
- 44 84. Gusnanto, A., et al., *Discriminatory cytokine profiles predict muscle function, fatigue and*
45 *cognitive function in patients with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome*
46 *(ME/CFS)*. medRxiv, 2020: p. 2020.08.17.20164715.
- 47 85. White, P.D., et al., *Immunological Changes After Both Exercise and Activity in Chronic Fatigue*
48 *Syndrome*. Journal of Chronic Fatigue Syndrome, 2004. **12**(2): p. 51-66.
- 49 86. Pan, Y., et al., *Alteration of Autonomic Nervous System Is Associated With Severity and*
50 *Outcomes in Patients With COVID-19*. Frontiers in Physiology, 2021. **12**(689).

- 1 87. Komaroff, A.L. and W.I. Lipkin, *Insights from myalgic encephalomyelitis/chronic fatigue*
2 *syndrome may help unravel the pathogenesis of postacute COVID-19 syndrome*. Trends in
3 molecular medicine, 2021. **27**(9): p. 895-906.
- 4 88. Sander, L.E. and J. Garaude, *The mitochondrial respiratory chain: A metabolic rheostat of*
5 *innate immune cell-mediated antibacterial responses*. Mitochondrion, 2018. **41**: p. 28-36.
- 6 89. Burtscher, J., et al., *Mitochondria: In the Cross Fire of SARS-CoV-2 and Immunity*. iScience,
7 2020. **23**(10): p. 101631.
- 8 90. Tay, M.Z., et al., *The trinity of COVID-19: immunity, inflammation and intervention*. Nature
9 Reviews Immunology, 2020. **20**(6): p. 363-374.
- 10 91. Arena, R., et al., *Shelter from the cytokine storm: Healthy living is a vital preventative*
11 *strategy in the COVID-19 era*. Progress in Cardiovascular Diseases, 2021.
- 12 92. Anand, S.K. and S.K. Tikoo, *Viruses as modulators of mitochondrial functions*. Adv Virol, 2013.
13 **2013**: p. 738794.
- 14 93. Welch, C., et al., *COVID-19 and Acute Sarcopenia*. Aging Dis, 2020. **11**(6): p. 1345-1351.
- 15 94. Morley, J.E., *COVID-19 — The Long Road to Recovery*. The journal of nutrition, health &
16 aging, 2020. **24**(9): p. 917-919.
- 17 95. NICE. *COVID-19 rapid guideline: managing the long-term effects of COVID-19*. 2021 [cited
18 2021 3rd December]; Available from: <https://www.nice.org.uk/guidance/ng188>.
- 19 96. Kingstone, T., et al., *Finding the 'right' GP: a qualitative study of the experiences of people*
20 *with long-COVID*. BJGP Open, 2020. **4**(5): p. bjgpopen20X101143.
- 21 97. Hayes, L.D., J. Ingram, and N.F. Sculthorpe, *More Than 100 Persistent Symptoms of SARS-*
22 *CoV-2 (Long COVID): A Scoping Review*. Frontiers in Medicine, 2021. **8**(2028).
- 23 98. Xiong, Q., et al., *Clinical sequelae of COVID-19 survivors in Wuhan, China: a single-centre*
24 *longitudinal study*. Clinical Microbiology and Infection, 2021. **27**(1): p. 89-95.
- 25 99. Machado, F.V.C., et al., *Construct validity of the Post-COVID-19 Functional Status Scale in*
26 *adult subjects with COVID-19*. Health and Quality of Life Outcomes, 2021. **19**(1): p. 40.
- 27 100. Jacobs, L.G., et al., *Persistence of symptoms and quality of life at 35 days after*
28 *hospitalization for COVID-19 infection*. PLOS ONE, 2020. **15**(12): p. e0243882.
- 29 101. Townsend, L., et al., *Persistent fatigue following SARS-CoV-2 infection is common and*
30 *independent of severity of initial infection*. PLOS ONE, 2020. **15**(11): p. e0240784.
- 31 102. Bellan, M., et al., *Respiratory and Psychophysical Sequelae Among Patients With COVID-19*
32 *Four Months After Hospital Discharge*. JAMA Network Open, 2021. **4**(1): p. e2036142-
33 e2036142.
- 34 103. Stavem, K., et al., *Persistent symptoms 1.5–6 months after COVID-19 in non-hospitalised*
35 *subjects: a population-based cohort study*. Thorax, 2021. **76**(4): p. 405-407.
- 36 104. van den Borst, B., et al., *Comprehensive Health Assessment 3 Months After Recovery From*
37 *Acute Coronavirus Disease 2019 (COVID-19)*. Clinical infectious diseases : an official
38 publication of the Infectious Diseases Society of America, 2021. **73**(5): p. e1089-e1098.
- 39 105. Taquet, M., et al., *Incidence, co-occurrence, and evolution of long-COVID features: A 6-month*
40 *retrospective cohort study of 273,618 survivors of COVID-19*. PLOS Medicine, 2021. **18**(9): p.
41 e1003773.
- 42 106. Faghy, M.A., et al., *The need for exercise sciences and an integrated response to COVID-19: A*
43 *position statement from the international HL-PIVOT network*. Progress in Cardiovascular
44 Diseases, 2021. **67**: p. 2-10.
- 45 107. Faghy, M.A., et al., *Integrated sports and respiratory medicine in the aftermath of COVID-19*.
46 The Lancet. Respiratory medicine, 2020. **8**(9): p. 852-852.

47